上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02607 上海医药

休市中 10-16 16:08:16

11.170

-0.080

-0.71%

最高11.390	最低11.150	成交量143.45万
今开11.290	昨收11.250	日振幅2.13%
总市值414.18亿	流通市值102.66亿	总股本37.08亿
成交额1,618万	换手率0.16%	流通股本9.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":11.17,"timestamp":1792138096008,"preClose":11.25,"halted":0,"volume":1434500,"delay":0,"changeRate":-0.0071111111111111175,"floatShares":919072704,"shares":3708000000,"eps":1.8074886041249731,"marketStatus":"休市中","change":-0.08,"latestTime":"10-16 16:08:16","open":11.29,"high":11.39,"low":11.15,"amount":16183454,"amplitude":0.021333,"askPrice":11.18,"askSize":2300,"bidPrice":11.17,"bidSize":1300,"shortable":3,"etf":0,"ttmEps":1.5097469162369817,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792459800000},"marketStatusCode":7,"adr":0,"listingDate":1305820800000,"exchange":"SEHK","adjPreClose":11.25,"dividendRate":0.046938,"openAndCloseTimeList":[[1792114200000,1792123200000],[1792126800000,1792137600000]],"volumeRatio":0.571485301666669,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":16.61,"timestamp":1792134000000,"preClose":16.76,"halted":0,"volume":14439600,"delay":0,"premium":"-42.70"}},"requestUrl":"/m/hq/s/02607","defaultTab":"news","newsList":[{"id":"1138239645","title":"上海医药（02607）发布公司公告","url":"https://stock-news.laohu8.com/highlight/detail?id=1138239645","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138239645?lang=zh_cn&edition=full","pubTime":"2026-10-16 16:43","pubTimestamp":1792140239,"startTime":"0","endTime":"0","summary":"上海医药（02607）近日在联交所发布公告。公告正文仅披露公司名称（Shanghai Pharmaceuticals Holding Co., Ltd.）及股票代码（02607）。除上述基本信息外，公告未包含任何财务数据、经营指标或具体事项说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674872321","title":"【投融资动态】前沿类脑中心天使轮融资，融资额2.5亿人民币，投资方为上海医药、四川省中试平台有限公司等","url":"https://stock-news.laohu8.com/highlight/detail?id=2674872321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674872321?lang=zh_cn&edition=full","pubTime":"2026-10-12 19:26","pubTimestamp":1791804371,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP于10月9日公布的信息整理，成都市前沿类脑人工智能创新中心有限公司天使轮融资，融资额2.5亿人民币，参与投资的机构包括上海医药，四川省中试平台有限公司，成都科创投集团。前沿类脑中心是一家脑机接口研发应用服务商，自主研发非侵入式脑机接口软硬件，包括双通道脑电+单通道心电多模态干电极采集模组，可实时捕捉脑电与生理信号。数据来源：天眼查APP以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200029706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","CNHmain","BK0099","UCmain","BK0097","BK1197","601607","BK0188","BK0012","BK0028","BK0175","BK0209","MUCmain","BK0183","MCNHmain","CYB","02607","BK0184","BK0020","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674843048","title":"股市必读：上海医药新发布《上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674843048","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674843048?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:43","pubTimestamp":1791740589,"startTime":"0","endTime":"0","summary":"当日关注点交易信息汇总：10月9日主力资金净流出1524.51万元，占总成交额5.3%；  公司公告汇总：氯维地平乳状注射液获国家药监局批准生产，公司已投入研发费用约5,220万元。公司公告汇总上海医药集团股份有限公司关于氯维地平乳状注射液获得批准生产的公告上海医药集团股份有限公司下属上海上药第一生化药业有限公司收到国家药监局颁发的氯维地平乳状注射液《药品注册证书》，该药品符合药品注册有关要求，批准生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0209","BK0012","BK1197","BK0028","BK0175","BK0097","BK0188","BK0187","601607","BK0184","BK0099","02607","BK0020","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134349315","title":"上海医药氯维地平乳状注射液获批生产 拓展高血压注射剂市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1134349315","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134349315?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:05","pubTimestamp":1791540339,"startTime":"0","endTime":"0","summary":"2026年10月10日，上海医药集团股份有限公司公告称，其控股子公司上海上药第一生化药业有限公司已收到国家药品监督管理局签发的《药品注册证书》，氯维地平乳状注射液获准生产。根据公告，氯维地平乳状注射液为化学药品3类仿制药，剂型为注射剂，规格为50ml:25mg和100ml:50mg，获批文号分别为国药准字H20266064、国药准字H20266065。IQVIA数据显示，2025年度中国大陆医院采购与氯维地平乳状注射液同机制的钙通道阻滞剂注射剂金额为91,139万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674737858","title":"上海医药(02607.HK)：氯维地平乳状注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2674737858","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674737858?lang=zh_cn&edition=full","pubTime":"2026-10-09 18:02","pubTimestamp":1791540130,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1197","02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674831293","title":"上海医药(601607.SH)：氯维地平乳状注射液获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2674831293","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674831293?lang=zh_cn&edition=full","pubTime":"2026-10-09 15:42","pubTimestamp":1791531746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药第一生化药业有限公司收到国家药品监督管理局颁发的关于氯维地平乳状注射液的《药品注册证书》，该药品获得批准生产。该药品主要用于治疗不适宜口服或预期口服药物治疗效果不佳的高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0028","BK0099","BK0209","BK0184","BK0175","BK0187","BK1197","BK0012","601607","BK0183","BK0097","BK0188","BK0020","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673801495","title":"股市必读：上海医药新发布《上海医药集团股份有限公司第九届董事会第五次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673801495","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673801495?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:07","pubTimestamp":1791392830,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，上海医药报收于16.22元，上涨1.38%，换手率0.41%，成交量11.42万手，成交额1.85亿元。公司公告汇总：上海医药董事会审议通过转让Zeus Investment Limited及其附属公司股权事项，标的公司企业价值为396,732,460美元。公司公告汇总上海医药集团股份有限公司第九届董事会第五次会议决议公告上海医药于2026年9月28日召开第九届董事会第五次会议，审议通过《关于转让Zeus Investment Limited及其附属公司股权的议案》和《关于高级管理人员年度经营业绩考核与薪酬方案》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800000736.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0184","02607","BK0196","BK0097","BK0175","BK0188","BK0020","BK1197","BK0099","601607","BK0187","BK0012","BK0183","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102279449","title":"上海医药更新2026年9月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1102279449","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102279449?lang=zh_cn&edition=full","pubTime":"2026-10-02 17:36","pubTimestamp":1790933785,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司于2026年10月2日披露截至2026年9月30日的证券变动月报。报告显示，本月公司已发行股份结构保持稳定，未发生新增发行、购回或注销情况。具体来看，截至2026年9月30日，公司H股普通股已发行股份数量为919,072,704股，与上个月持平，库存股份为0股；A股普通股已发行股份数量为2,789,289,105股，库存股份为0股，两者均未发生变动。公告披露，公司在报告期内无任何期权或股权激励计划相关变动，也不存在任何购回及注销活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671622323","title":"9.48亿元买入、13.36亿元卖出！上海医药拟出售所持ZIL股权，标的去年营收超3.5亿澳元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671622323","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671622323?lang=zh_cn&edition=full","pubTime":"2026-09-30 07:51","pubTimestamp":1790725887,"startTime":"0","endTime":"0","summary":"9月29日晚间，上海医药（SH601607，股价16元，市值593亿元）公告称，公司拟与春华资本共同出售ZeusInvestmentLimited（以下简称ZIL或标的公司）及其附属公司全部股权，标的公司企业价值确定为3.97亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609303887043645.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609303887043645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142181701","title":"上海医药（02607）拟3.97亿美元剥离Vitaco资产，预计收回不少于1.99亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142181701","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142181701?lang=zh_cn&edition=full","pubTime":"2026-09-29 21:26","pubTimestamp":1790688366,"startTime":"0","endTime":"0","summary":"上海医药集团股份有限公司9月30日在港交所发布海外监管公告称，公司第九届董事会第五次会议已于2026年9月28日召开，并审议通过转让Zeus Investment Limited及其附属公司股权等议案。此次交易不构成关联交易，也不构成重大资产重组。根据双方约定的营运资金、净负债及资本支出等调整，预计交割日标的公司股权价值不低于3.499亿美元。上海医药表示，将根据交易进展及时履行信息披露义务，并提醒投资者注意相关风险。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670253228","title":"上海医药（601607）披露紫杉醇注射液获得批准生产的公告，9月28日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670253228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670253228?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:14","pubTimestamp":1790604868,"startTime":"0","endTime":"0","summary":"截至2026年9月28日收盘，上海医药报收于15.89元，较前一交易日下跌0.81%，最新总市值为589.26亿元。该股当日开盘16.01元，最高16.11元，最低15.83元，成交额达1.41亿元，换手率为0.32%。近日，上海医药集团股份有限公司发布关于紫杉醇注射液获得批准生产的公告。公告显示，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的《药品注册证书》，紫杉醇注射液获得批准生产。截至公告日，公司已投入研发费用约451万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800034726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","02607","BK0184","BK0175","BK0028","BK0196","BK0209","BK0097","BK0188","BK0187","BK0012","BK0183","BK0020","BK1197","601607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145836349","title":"上海医药（02607）三款仿制药同日获批生产　覆盖肿瘤、消化及抗真菌三大领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1145836349","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145836349?lang=zh_cn&edition=full","pubTime":"2026-09-28 18:11","pubTimestamp":1790590267,"startTime":"0","endTime":"0","summary":"2026年9月29日，上海医药集团股份有限公司公告称，公司旗下三家子公司分别收到国家药品监督管理局核发的药品注册证书，涉及紫杉醇注射液、艾司奥美拉唑镁肠溶胶囊及注射用硫酸艾沙康唑三款产品，均已获准生产。以下为具体信息：。证书编号：2026S03433；规格5 ml：30 mg；化学药品4类，批准文号“国药准字H20265984”。市场规模：IQVIA数据显示，2025年中国大陆医院采购额为3.61亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670233026","title":"上海医药最新公告：艾司奥美拉唑镁肠溶胶囊获批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670233026","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670233026?lang=zh_cn&edition=full","pubTime":"2026-09-28 17:42","pubTimestamp":1790588538,"startTime":"0","endTime":"0","summary":"上海医药(601607.SH)公告称，公司下属常州制药厂收到国家药监局颁发的艾司奥美拉唑镁肠溶胶囊《药品注册证书》，该药品获得批准生产。该药品适用于胃食管反流病、根除幽门螺杆菌等，公司已投入研发费用约519万元。2025年中国大陆医院采购该药品金额为6.39亿元。此次获批有利于扩大市场份额，但存在销售不达预期风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800022872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0175","BK0184","BK0209","BK0099","BK0183","BK0028","BK0012","BK0196","BK0187","BK0097","02607","BK0020","BK0188","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670877212","title":"上海医药(601607.SH)：注射用硫酸艾沙康唑获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670877212","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670877212?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:27","pubTimestamp":1790584048,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上药东英(江苏)药业有限公司(以下简称“上药东英”)收到国家药品监督管理局(以下简称“国家药监局”)颁发的关于注射用硫酸艾沙康唑(以下简称“该药品”)的《药品注册证书》(证书编号：2026S03379)，该药品获得批准生产。注射用硫酸艾沙康唑适用于治疗成人和1岁及以上儿童患者下列感染：侵袭性曲霉病、侵袭性毛霉病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0175","BK0209","BK0020","BK0183","BK0028","02607","BK0012","BK0097","601607","BK0188","BK0184","BK0099","BK1197","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670723287","title":"上海医药：下属公司紫杉醇注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2670723287","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670723287?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:17","pubTimestamp":1790583420,"startTime":"0","endTime":"0","summary":"9月28日，上海医药（601607/02607）发布公告，近日，公司下属上海金和生物制药有限公司收到国家药品监督管理局颁发的关于紫杉醇注射液的《药品注册证书》，该药品获得批准生产。紫杉醇注射液适用于进展期卵巢癌的一线、后继治疗及淋巴结阳性的乳腺癌患者在含阿霉素标准方案联合化疗后的辅助治疗等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885220435.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885220435.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0175","BK0028","BK0183","BK0184","BK0012","BK0196","BK1197","BK0209","BK0020","601607","BK0097","BK0099","02607","BK0188","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184095522","title":"上海医药2026年中期业绩：营收1474.70亿元，经调整净利润28.28亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184095522","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184095522?lang=zh_cn&edition=full","pubTime":"2026-09-17 16:46","pubTimestamp":1789634812,"startTime":"0","endTime":"0","summary":"上海医药公布2026年中期报告，报告期内，公司实现营业收入1474.70亿元，同比增长4.15%。经调整后净利润28.28亿元，同比增长1.65%。同期经营活动现金流净流入44.50亿元，同比大幅增长349.78%。报告期内，公司研发投入总额10.53亿元，占其医药工业销售收入的7.98%。上海医药管理层在报告中透露，本集团在坚持创新转型的基础上，将持续优化产品结构、强化市场推广和费用控制。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"上海医药2026年中期业绩：营收1474.70亿元，经调整净利润28.28亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02607"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507911","title":"每周股票复盘：上海医药（601607）盐酸林可霉素通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507911","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507911?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:13","pubTimestamp":1789236790,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，上海医药报收于16.29元，较上周的16.62元下跌1.99%。公司公告汇总上海医药集团股份有限公司发布2026年半年度权益分派实施公告，本次利润分配经2025年年度股东会审议通过。上海医药集团股份有限公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的《药品补充申请批准通知书》，盐酸林可霉素注射液通过仿制药质量和疗效一致性评价。2025年7月，上药禾丰提交一致性评价申请并获受理，截至公告日研发投入约197万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0183","BK0196","BK0209","BK0020","BK0012","BK1197","601607","BK0099","BK0175","BK0028","BK0184","BK0187","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666823540","title":"上海医药：每股派0.10元，股权登记日为9月17日","url":"https://stock-news.laohu8.com/highlight/detail?id=2666823540","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666823540?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:52","pubTimestamp":1789116720,"startTime":"0","endTime":"0","summary":"南财智讯9月11日电，上海医药发布2026年半年度权益分派实施公告，每股派0.10元（含税），股权登记日为9月17日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113872118437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113872118437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0020","601607","BK0175","BK0187","BK0209","02607","BK0196","BK0188","BK0183","BK0012","BK0184","BK0097","BK0099","BK1197","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666974865","title":"股市必读：上海医药新发布《上海医药集团股份有限公司2026年半年度权益分派实施公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666974865","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666974865?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:10","pubTimestamp":1789060222,"startTime":"0","endTime":"0","summary":"公司公告汇总：上海医药下属上海禾丰制药有限公司盐酸林可霉素注射液通过仿制药一致性评价，2025年该药品中国大陆医院采购金额为2168万元，截至公告日研发投入约197万元。公司公告汇总上海医药集团股份有限公司2026年半年度权益分派实施公告本次利润分配经2026年6月25日召开的2025年年度股东会审议通过，每股派发现金红利0.10元（含税），以公司总股本3,708,361,809股为基数，共计派发现金红利370,836,180.90元，其中A股现金红利278,928,910.50元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0020","601607","BK0187","BK0188","BK1197","BK0012","BK0028","02607","BK0184","BK0209","BK0099","BK0183","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567287","title":"上海医药(601607.SH)下属公司盐酸林可霉素注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567287","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666567287?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:53","pubTimestamp":1789037606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海禾丰制药有限公司收到国家药品监督管理局颁发的关于盐酸林可霉素注射液的《药品补充申请批准通知书》，该药品通过仿制药一致性评价。该药品适用于由链球菌、肺炎球菌和葡萄球菌等敏感菌株引起的严重感染，但仅适用于对青霉素过敏的患者或经医生判断不宜使用青霉素的患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494560.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0184","BK0097","BK0188","BK1197","BK0012","BK0183","601607","BK0196","BK0020","BK0028","BK0187","BK0209","BK0099","BK0175","02607"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.shaphar.com.cn","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0285},{"period":"3month","weight":-0.0646},{"period":"6month","weight":0.0041},{"period":"1year","weight":-0.0204},{"period":"ytd","weight":0.027}],"compareEarnings":[{"period":"1week","weight":-0.001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0153},{"period":"6month","weight":-0.0754},{"period":"1year","weight":-0.0657},{"period":"ytd","weight":-0.0563}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海医药集团股份有限公司是一家主要从事医药分销业务的中国公司。该公司主要经营四个业务分部。工业分部主要从事药品及保健品的研发、生产和销售。分销分部主要从事向医药制造商及配药商提供分销、仓储和其他增值医药供应链解决方案及相关服务。零售分部主要从事经营及加盟零售药店网络。其他分部主要从事其他业务。该公司主要在国内市场经营其业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.533333,"avgChangeRate":0.005809},{"month":2,"riseRate":0.533333,"avgChangeRate":0.014994},{"month":3,"riseRate":0.533333,"avgChangeRate":0.00954},{"month":4,"riseRate":0.533333,"avgChangeRate":0.000637},{"month":5,"riseRate":0.466667,"avgChangeRate":-0.003705},{"month":6,"riseRate":0.5,"avgChangeRate":-0.010272},{"month":7,"riseRate":0.375,"avgChangeRate":-0.010292},{"month":8,"riseRate":0.375,"avgChangeRate":0.007403},{"month":9,"riseRate":0.3125,"avgChangeRate":0.01139},{"month":10,"riseRate":0.3125,"avgChangeRate":-0.019552},{"month":11,"riseRate":0.466667,"avgChangeRate":0.029704},{"month":12,"riseRate":0.533333,"avgChangeRate":-0.01256}],"exchange":"SEHK","name":"上海医药","nameEN":"SH PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,02607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(02607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(02607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}